Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
AIM 16 February 2023 NOTICE 16/02/2023 - 07:00 NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM Pursuant to AIM Rule 41 the following securities have been cancelled from trading on AIM with...
eeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administ ...
4d Pharma PLC 15 February 2023 4D pharma plc (in administration) Cancellation of admission to trading on AIM Leeds, UK, 15 February 2023 - 4D pharma plc (the "Company") (AIM: DDDD...
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by ...
4d Pharma PLC 02 February 2023 4D pharma plc (in administration) 4D pharma Announces Updated Results from the Renal Cell Carcinoma Cohort of the Phase I/II Study of the Combination of MRx0518 and...
4d Pharma PLC 16 January 2023 4D pharma Announces Result of General Meeting Leeds, UK - January 16, 2023 - 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the...
4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lif ...
4d Pharma PLC 30 December 2022 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION...
4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive e ...
4d Pharma PLC 16 November 2022 4D pharma's Blautix(R) Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics Leeds, UK - November 15, 2022 - 4D pharma plc...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
